ETF profile for First Trust Nyse Arca Biotechnology (FBT) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
FBT ETF Profile
| Family: |
First Trust |
| Name: |
First Trust NYSE Arca Biotechnology Index Fund |
|
|
| Inception Date: |
19-Jun-2006 |
| Termination Date: |
|
| Investment Objective: |
The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible before fees and expenses the price and yield of the NYSE Arca Biotechnology Index. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Halozyme Therapeutics Inc. |
HALO |
3.6649% |
| Biogen Inc. |
BIIB |
3.6544% |
| Regeneron Pharmaceuticals Inc. |
REGN |
3.5652% |
| Exelixis Inc. |
EXEL |
3.5453% |
| Alkermes Plc |
ALKS |
3.5351% |
| Genmab A/S (ADR) |
GMAB |
3.5062% |
| BeOne Medicines Ltd. (ADR) |
ONC |
3.5043% |
| Amgen Inc. |
AMGN |
3.5033% |
| United Therapeutics Corporation |
UTHR |
3.4602% |
| argenx SE (ADR) |
ARGX |
3.4492% |
|
Top 10 Holdings Weight: |
35.4% |
| Number of Holdings: |
31 |
| Shares Outstanding: |
11,050,002 |
| Total Net Assets: |
3,013,114,624 |
| NAV: |
272.54 |
| Net Expense Ratio: |
0.55% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
US |
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Domestic |
